THE WHAT? OneSkin has closed an over-subscribed Series A funding round led by Selva Ventures. Plus Capital, Unilever Ventures, Able Partners, SOSV and Meta Planet were also named as participants. This latest injection of funds brings the biotech brand’s total to US$20 million.

THE DETAILS Resources from funding will fuel accelerated research and novel formulas, delivering expanded longevity solutions and rewriting a new way forward for the anti-aging skincare industry. The funding will also power an increase in human capital focused on growth opportunities and new sales channels for the business.

THE WHY?  Carolina Oliveira, Co-Founder and CEO, explains, “At OneSkin, we are excited to announce this new round of funding, which will further drive our mission to transform how we think about our skin, not only by optimizing our aesthetics using cutting-edge science, but also focusing on its functional role as our largest organ and the impact in our overall health and longevity.”